Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients.

[1]  L. Leibovici,et al.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. , 2014, The Cochrane database of systematic reviews.

[2]  H. Koga,et al.  Efficacy and safety of rituximab treatment in Indian pemphigus patients , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  M. Jonkman,et al.  Low‐dose rituximab is effective in pemphigus , 2012, The British journal of dermatology.

[4]  P. Emery,et al.  Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis , 2011, Rheumatology.

[5]  S. Kim,et al.  Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients , 2011, The British journal of dermatology.

[6]  D. Zillikens,et al.  Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. , 2011, Journal of the American Academy of Dermatology.

[7]  S. Beissert,et al.  Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. , 2010, The Journal of investigative dermatology.

[8]  D. Zillikens,et al.  Rituximab in Severe Pemphigus , 2009, Annals of the New York Academy of Sciences.

[9]  R. Eming,et al.  B-cell-directed therapy for inflammatory skin diseases. , 2009, The Journal of investigative dermatology.

[10]  D. Murrell,et al.  Interventions for pemphigus vulgaris and pemphigus foliaceus. , 2009, The Cochrane database of systematic reviews.

[11]  H. Shimizu,et al.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.

[12]  D. Zillikens,et al.  Recommendations for the use of rituximab (anti‐CD20 antibody) in the treatment of autoimmune bullous skin diseases § , 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[13]  R. Gniadecki,et al.  Two courses of rituximab (anti‐CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris , 2008, International journal of dermatology.

[14]  J. Roujeau,et al.  A single cycle of rituximab for the treatment of severe pemphigus. , 2007, The New England journal of medicine.

[15]  R. Corona,et al.  Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. , 2007, Archives of dermatology.

[16]  D. Fanoni,et al.  Treatment of Refractory Pemphigus with the Anti-CD20 Monoclonal Antibody (Rituximab) , 2007, Dermatology.

[17]  R. Eming,et al.  Rituximab (Anti-CD20 Monoclonal Antibody) – Ultimate or First Choice in Pemphigus? , 2007, Dermatology.

[18]  L. Cavacini,et al.  Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. , 2006, The New England journal of medicine.

[19]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[20]  P. Emery,et al.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.

[21]  M. Leandro,et al.  Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[22]  C. Hoyle,et al.  Response of pemphigus vulgaris to anti‐CD20 antibody therapy (rituximab) may be delayed , 2006, Clinical and experimental dermatology.

[23]  Y. Hanakawa,et al.  Desmosomes and disease: pemphigus and bullous impetigo. , 2004, Current opinion in cell biology.

[24]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[25]  D. Mimouni,et al.  Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. , 2003, Journal of the American Academy of Dermatology.

[26]  Thomas G. Salopeka,et al.  Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder ☆ ☆☆ ★ , 2002 .

[27]  S. Knowles,et al.  THE RISKS OF SYSTEMIC CORTICOSTEROID USE , 1998 .

[28]  D. Maloney,et al.  IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma , 1997 .

[29]  Masayuki Amagai,et al.  Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion , 1991, Cell.

[30]  J. Stanley.  Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. , 1989, The Journal of clinical investigation.

[31]  J. Voorhees,et al.  Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. , 1982, The New England journal of medicine.

[32]  S. Blaise,et al.  Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). , 2004, Archives of dermatology.